Skip to main content
. 2023 Jul 8;16:73. doi: 10.1186/s13045-023-01476-8

Fig. 2.

Fig. 2

Outcomes of the AML cohort. A Relapse-free survival for the entire cohort, B overall survival for the entire cohort, C overall survival by presence of TP53 mutation or MECOM rearrangement, and D overall survival by clinical history of prior hypomethylating agent or chemotherapy exposure for antecedent hematologic malignancy and by presence of TP53 mutation or MECOM rearrangement